Sign In
Buy MGTX
$9.39
+0.150 (+1.62%)
At Close: Jun 03, 2026
MeiraGTx Holdings plc (MGTX) Presents at RBC Capital Markets Virtual Ophthalmology Conference Transcript
04:45pm, Friday, 27'th Mar 2026
MeiraGTx Holdings plc (MGTX) Presents at RBC Capital Markets Virtual Ophthalmology Conference Transcript
Alexandria Forbes Sells 62,000 Shares of MeiraGTx (NASDAQ:MGTX) Stock
04:22am, Friday, 27'th Mar 2026
MeiraGTx Holdings PLC (NASDAQ: MGTX - Get Free Report) CEO Alexandria Forbes sold 62,000 shares of the stock in a transaction that occurred on Tuesday, March 24th. The shares were sold at an average p
MeiraGTx Holdings PLC (MGTX) Q4 Earnings and Revenues Surpass Estimates
10:16am, Thursday, 26'th Mar 2026
MeiraGTx Holdings PLC (MGTX) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of a loss of $0.6 per share. This compares to a loss of $0.5 per share a year ago
FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tract MeiraGTx to hol
MeiraGTx Holdings PLC (NASDAQ:MGTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
04:28am, Monday, 16'th Mar 2026
Shares of MeiraGTx Holdings PLC (NASDAQ: MGTX - Get Free Report) have received an average rating of "Moderate Buy" from the seven ratings firms that are covering the firm, Marketbeat Ratings reports.
MeiraGTx Holdings PLC (NASDAQ:MGTX) Receives Average Rating of “Moderate Buy” from Analysts
03:29am, Thursday, 19'th Feb 2026
MeiraGTx Holdings PLC (NASDAQ: MGTX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the company, Marketbeat Ratings repo
ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
08:00am, Tuesday, 03'rd Feb 2026
BOSTON, Feb. 3, 2026 /PRNewswire/ -- ZipBio, a biotechnology company pioneering AI-driven protein therapeutics, announced an exclusive license agreement with MeiraGTx Holdings plc (Nasdaq: MGTX), a v
AMH Equity Ltd Invests $658,000 in MeiraGTx Holdings PLC $MGTX
03:22am, Sunday, 18'th Jan 2026
AMH Equity Ltd acquired a new stake in shares of MeiraGTx Holdings PLC (NASDAQ: MGTX) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commissi
MeiraGTx Holdings PLC (NASDAQ:MGTX) Given Average Rating of “Moderate Buy” by Analysts
01:26am, Wednesday, 31'st Dec 2025
MeiraGTx Holdings PLC (NASDAQ: MGTX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six research firms that are currently covering the stock, MarketBeat reports. One
Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference
03:00pm, Thursday, 20'th Nov 2025
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Graviton Bioscience Corporation, a clinical-stage biotechnology company developing selective ROCK2 inhibitors for metabolic, inflammatory, fibrotic, and centr
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Lags Revenue Estimates
10:15am, Thursday, 13'th Nov 2025
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.54 per share a year ago.
MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
08:00am, Thursday, 13'th Nov 2025
LONDON and NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced financial and operatio
MeiraGTx: Latest Eli Lilly Partnership Ignites Riboswitch Technology Potential
03:30pm, Wednesday, 12'th Nov 2025
MeiraGTx Holdings plc secures a transformative partnership with Eli Lilly, granting worldwide rights to its AAV-AIPL1 gene therapy for LCA4. MGTX receives $75 million upfront, up to $400 million in mi
Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease
09:10am, Monday, 10'th Nov 2025
MeiraGTx Holdings has signed a deal with Eli Lilly , potentially worth over $475 million, granting the pharma giant rights to its experimental gene therapy for a rare, inherited disorder that causes s
LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic coll
